• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
10x Genomics, Inc. (TXG) Stock Price, News & Analysis

10x Genomics, Inc. (TXG) Stock Price, News & Analysis

Currency in USD Disclaimer

$15.87

$0.64

(4.2%)

Day's range
$15.39
Day's range
$16.13
50-day range
$12.95
Day's range
$23.07
  • Country: US
  • ISIN: US88025U1097
52 wk range
$12.95
Day's range
$57.9
  • CEO: Dr. Serge Saxonov Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 3.90
  • Piotroski Score 5.00
  • Grade Neutral
  • Symbol (TXG)
  • Company 10x Genomics, Inc.
  • Price $15.87
  • Changes Percentage (4.2%)
  • Change $0.64
  • Day Low $15.39
  • Day High $16.13
  • Year High $57.90

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/13/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $28.50
  • High Stock Price Target $46.00
  • Low Stock Price Target $24.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.24
  • Trailing P/E Ratio -9.76
  • Forward P/E Ratio -9.76
  • P/E Growth -9.76
  • Net Income $-255,099,000

Income Statement

Quarterly

Annual

Latest News of TXG

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

10x Genomics, Inc. Frequently Asked Questions

  • What were the earnings of TXG in the last quarter?

    In the last quarter 10x Genomics, Inc. earnings were on Tuesday, October, 29th. The 10x Genomics, Inc. maker reported -$0.30 EPS for the quarter, beating analysts' consensus estimates of -$0.34 by $0.04.

  • What is the 10x Genomics, Inc. stock price today?

    Today's price of 10x Genomics, Inc. is $15.87 — it has increased by +4.2% in the past 24 hours. Watch 10x Genomics, Inc. stock price performance more closely on the chart.

  • Does 10x Genomics, Inc. release reports?

    Yes, you can track 10x Genomics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the 10x Genomics, Inc. stock forecast?

    Watch the 10x Genomics, Inc. chart and read a more detailed 10x Genomics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is 10x Genomics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by 10x Genomics, Inc. stock ticker.

  • How to buy 10x Genomics, Inc. stocks?

    Like other stocks, TXG shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is 10x Genomics, Inc.'s EBITDA?

    10x Genomics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in 10x Genomics, Inc.’s financial statements.

  • What is the 10x Genomics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.4122965379, which equates to approximately -41.23%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in 10x Genomics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including 10x Genomics, Inc.'s financials relevant news, and technical analysis. 10x Genomics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for 10x Genomics, Inc. stock currently indicates a “sell” signal. For more insights, review 10x Genomics, Inc.’s technical analysis.

  • A revenue figure for 10x Genomics, Inc. for its last quarter?

    10x Genomics, Inc. published it's last quarterly revenues at $151.65 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.